Chemoprevention of lung cancer
- 1 July 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 10 (4) , 279-283
Abstract
Lung cancer is one of the major causes of cancer-related deaths. Grim mortality figures argue powerfully for new approaches to control this disease. Chemoprevention is the use of specific natural or synthetic chemical agents to reverse, suppress, or prevent carcinogenic progression to invasive cancer. The current article focuses on the field of lung cancer chemoprevention and recent advances. Lung cancer biology and general principles of prevention strategies are also described. Trials in lung cancer chemoprevention have so far produced either neutral or harmful primary end point results whether in the primary, secondary and tertiary settings. The data suggest that lung cancer was not prevented by beta-carotene, alpha-tocopherol, retinal, retinyl palmitate, N-acetylcysteine, or isotretinoin in smokers. The results from the recently completed Canadian study of anethole dithiolethione in smokers with bronchial dysplasia as well secondary analyses of the phase III trials involving selenium and data from the US Intergroup NCI-91-0001 supporting treatment with isotretinoin in never and former smokers are hopeful and may help define new avenues of chemopreventive treatment after scientists and clinicians analyze the information generated. The concept of chemoprevention in lung cancer is still in its infancy but one day may have a significant impact on the incidence and mortality of this leading cancer threat. An improved understanding of carcinogenesis and cancer prevention mechanisms will no doubt aid in the design of future clinical trials and in the validation of candidate agents as well as the development of new targets. Planned or ongoing trials currently are targeting important molecular markers of lung carcinogenesis and progression including cyclooxygenase-2, the ras-signaling pathway through farnesyl transferase inhibitors and the tyrosine kinase/epidermal growth factor receptor pathway. Until such studies are completed however, no drug or drug combination should be used for lung cancer prevention outside of a clinical study.Keywords
This publication has 28 references indexed in Scilit:
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI: Journal of the National Cancer Institute, 1998
- Recent Advances in Chemoprevention of CancerScience, 1997
- Molecular Damage in the Bronchial Epithelium of Current and Former SmokersJNCI: Journal of the National Cancer Institute, 1997
- Clonal Genetic Alterations in the Lungs of Current and Former SmokersJNCI: Journal of the National Cancer Institute, 1997
- The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male SmokersNew England Journal of Medicine, 1994
- Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 1990
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI: Journal of the National Cancer Institute, 1989
- 13-cis-Retinoic Acid in the Treatment of Oral LeukoplakiaNew England Journal of Medicine, 1986
- Changes in Bronchial Epithelium in Relation to Cigarette Smoking and in Relation to Lung CancerNew England Journal of Medicine, 1961